HSBC Thinks AbbVie Can Climb to $315. Here's the Bull Case in Plain English.
HSBC Thinks AbbVie Can Climb to $315. Here's the Bull Case in Plain English. The Globe and Mail
Covered in this story
What has happened since
- AbbVie is up 2.9% since this was published, 2 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on AbbVie
- Bank of America: $262 → $289 by Sep 2027 · Buy via AOL.com
- Bank of America: $249 → $282 by Sep 2027 · Buy via Investing.com
- Wells Fargo: $250 → $300 by Aug 2027 · Overweight via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ABBV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on AbbVie →Dalsna Finance is currently tracking 46 stories mentioning AbbVie, the earliest published 29 Apr 2026.
Summary aggregated from The Globe and Mail's public RSS feed. The full reporting belongs to The Globe and Mail — please read it on their site.